Connected health · Medical devices · Clinical technology
I turn healthcare complexity into solutions clients buy and services they value.
I’ve been the founder building the technology, the client selecting it, and the executive accountable for delivery. I bring the domain knowledge solution architects depend on—and the experience to turn that knowledge into revenue through paid discovery, solution definition, and delivery leadership.
Diabetech founder · Former Senior Director, Digital Clinical Development & Head of Innovation Lab, Ultragenyx · Former Business Analyst, Verizon
Start with your challenge
A few conversations we might have: the problem you’re facing, the experience I bring, and where I would start.
Study access
I’ve led loaner-device services, global wireless connectivity, and participant support. In the DDC workflow I describe, participants logged into a web app and could use different compatible devices; free study loaners provided an access option.
Explore the experienceVendor delivery
I’ve led IQVIA vendor management, Dexcom licensing negotiations, and development of an internal alternative that strengthened vendor accountability. That alternative served its strategic purpose without entering production. I would start with the delivery gap and the options we can realistically execute.
Explore the experienceSolution definition
At Ultragenyx, I built a clinical technology organization connecting product, engineering, quality, informatics, and service operations. I bring those perspectives into the conversation so the solution accounts for the people, workflows, and responsibilities around the technology.
Explore the experienceConnected health
With GlucoMON and ADMS, I connected glucose measurements to wireless delivery, analysis, and family or caregiver notifications. I look at the whole path: how data is captured, who needs it, and what happens when it arrives.
Explore the experienceClinical workflows
I designed and deployed Rarify for patient and site data capture, decentralized research, and longitudinal monitoring. I would start with the participant and site workflows, then define the technology and support needed to make them work.
Explore the experienceCommercial services
My experience spans enterprise commercialization, technology partnerships, and the client side of selection and delivery. I would start with the client’s problem and define a clear, paid scope for discovery, solution definition, or delivery leadership.
Explore the experienceUse a topic or question to find related records.
At a glance
Each statement has its own scope. Open the record for responsibilities, dates, evidence limits, and source context.
See supporting recordsKeyword search may miss the connection. Explore the featured experience, browse the complete index, or ask me about your challenge.
Built a global clinical technology organization connecting product, engineering, quality, informatics, and service operations around rare-disease research.
2019–2024
Designed and deployed a GCP-aligned platform for collaborative patient/site data capture, decentralized research, and longitudinal disease monitoring.
2019–2024
Led and developed a team responsible for selecting, building, validating, and supporting patient-reported clinical data capabilities.
Ultragenyx · 2019–2024
Led CGM product management, strategy, Dexcom licensing negotiations, and IQVIA vendor management. The Dexcom-related Rarify mobile and cloud components did not enter production but created a credible IQVIA replacement threat. Kevin reports that IQVIA’s Dexcom sensor data contributed to evidence supporting FDA accelerated approval of Genglycos (DTX401) for GSDIa.
Ultragenyx · 2019–2024; subsequent approval milestone · 2026
Supported an Ultragenyx-sponsored disease monitoring program with Yale and the XLH Network, connecting longitudinal research to participant experience.
2019–2023
Brought patient-reported, clinical, device, and operational data together across natural-history, interventional, and long-term monitoring work.
Ultragenyx · 2019–2024
Connected data structures, provenance, business rules, quality monitoring, and decision workflows across patient, device, and study operations.
Ultragenyx · 2019–2024
Evaluated technology in the context of clinical need, economics, implementation, quality, and continuing service responsibility.
Enterprise technology, Diabetech, and Ultragenyx
Embedded quality and validation into development, release, change management, and continuing service operations.
Ultragenyx · 2019–2024
Extended clinical technology delivery into site training, loaner devices, wireless connectivity, support, and operational accountability.
Ultragenyx · 2019–2024
Built and commercialized connected diabetes devices, hosted data systems, clinical decision-support workflows, and remote-care programs.
2001–2018
Integrated medical-device data capture, wireless networks, automated analysis, trend reporting, and family/caregiver notifications.
Diabetech · 2000s–2010s
Connected home sample collection, laboratory processing, digital results, patient onboarding, and follow-up into a usable diagnostic service.
Diabetech / remote-care programs
Extended connected glucose telemetry into payer- and employer-facing care programs with diagnostics, logistics, engagement, clinical workflows, and reporting.
Operating phase emphasized in career records: 2007–2012
Combined connected glucose data, home A1c, remote enrollment, patient support, physician participation, and payer-aware operations.
2006–2007
Designed technology, research procedures, home diagnostics, patient materials, and behavior-support workflows within a Medicaid disease-management environment.
2009–2011 program period
Connected remote diabetes services to physician participation, patient support, clinical evidence, and commercial reimbursement.
Diabetech / HealthCordia era
Extended connected-care experience into community recruitment, health education, patient registries, and U.S./U.K. programs.
Primary scaling phase: 2012–2018; earlier platform activity documented
Designed community-health participation around family influence, low-friction enrollment, relevant messaging, and links to health services.
2009–2011 and subsequent scaling
Adapted remote-monitoring and self-care workflows to pediatric diabetes and diabetes-in-pregnancy research in the U.K.
Pediatric T1D: 2010–2017; diabetes in pregnancy: 2010–2015
Connected wireless glucose information with patient-selected supporters and behaviorally informed engagement.
2009–2011 research and publication period
Contributed to observational, interventional, remote-monitoring, and disease-monitoring research across diabetes and rare disease.
2002–2024
Helped develop a federally supported pediatric remote-monitoring program combining wireless glucose data, support, and outcomes analysis.
2006–2009
Designed the full set of interactions that allow a patient to enter a service, participate, receive value, and remain connected to care or research.
Across remote care, clinical development, and patient education
Used physical and digital channels within one operating model so participation could fit the person rather than depend on a website.
Diabetech, Healthimo, and continuing program design
Brought patient and family experience into product requirements, clinical program design, education, and sustained engagement.
Diabetes community and Ultragenyx portfolio
Turned clinical and commercial needs into roadmaps, funded capabilities, delivery organizations, partner decisions, and measurable operating work.
Enterprise platforms, connected health, and Ultragenyx
Connected product capability with channels, partner economics, reimbursed services, and commercially workable delivery models.
1990s–present
Built an enterprise foundation in complex systems, procurement, mobile platforms, international customers, and integrated partner distribution.
1991–2002
Proposed a governed operating layer connecting cross-system data, trusted signals, interpretation, and accountable action across clinical trials.
March 2026 concept brief
Applied consent, provenance, human review, and controlled workflows to exploratory AI use in patient information and operations.
2024–2026 independent design work; earlier operating foundations
Explored a consent-aware way to turn patient-authored narratives into useful health biographies and structured longitudinal information.
Independent work beginning in 2024
Co-authored Sugar Surfing with Stephen W. Ponder, supporting CGM use by people with type 1 diabetes and clinicians. Kevin reports that Dexcom purchased copies in bulk to educate its sales representatives and distribute to prescribing endocrinologists.
Published 2015; continuing patient/provider education and publishing
Manages the people, production, commerce, distribution, and customer experience required to turn specialist knowledge into published products.
Established publishing imprint; independent work continues in 2026
Explored how sensors, delivery devices, communications, software, and human oversight fit into a broader automated-care system.
Early architecture work and 2014 educational presentation
Connects patient selection, intervention choices, devices, services, governance, and feedback into a care program that can adapt over time.
Historical operating experience; current design perspective in 2026
Contributed to discussions about diabetes self-care, remote care, and the practical conditions under which patients could obtain support.
Texas diabetes-care advocacy · 2000s
A traceable set of journal articles, conference abstracts, public records, and historical reporting supports the career narrative.
2002–2021 publication trail; continuing professional work
Extended Operational Telemetry into signal design, launch readiness, study execution, and traceable decisions across the trial lifecycle.
May 2026 paper and published website
A structured method for examining endpoint workflows, sources, devices, site burden, handoffs, and governance before first patient in.
Trial Telemetry framework · 2026
For AI-assisted review
40 detailed records. Named projects, responsibilities, dates, source context, and cross-references.